Cargando…
Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm
BACKGROUND: A controlled randomized trial was performed on a well-managed conventional French 180-sow farm. The trial compared the growth performances of piglets vaccinated at weaning (single shot) either with a commercial monovalent Mycoplasma hyopneumoniae bacterin vaccine or with a commercial biv...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772722/ https://www.ncbi.nlm.nih.gov/pubmed/29375890 http://dx.doi.org/10.1186/s40813-017-0077-y |
_version_ | 1783293456751263744 |
---|---|
author | Duivon, Didier Corrégé, Isabelle Hémonic, Anne Rigaut, Martial Roudaut, David Jolie, Rika |
author_facet | Duivon, Didier Corrégé, Isabelle Hémonic, Anne Rigaut, Martial Roudaut, David Jolie, Rika |
author_sort | Duivon, Didier |
collection | PubMed |
description | BACKGROUND: A controlled randomized trial was performed on a well-managed conventional French 180-sow farm. The trial compared the growth performances of piglets vaccinated at weaning (single shot) either with a commercial monovalent Mycoplasma hyopneumoniae bacterin vaccine or with a commercial bivalent vaccine (Porcilis® PCV M Hyo) against M. hyopneumoniae and porcine circovirus 2 (PCV2). The farm’s porcine reproductive and respiratory syndrome status was stable, and most diseases (enzootic pneumonia, atrophic rhinitis, post-weaning multisystemic wasting syndrome) were controlled by routine vaccination. RESULTS: During the post-weaning phase, the growth performances of the piglets vaccinated with the bivalent vaccine were not significantly different from those vaccinated with the monovalent vaccine. However, during the fattening phase the group vaccinated with the bivalent vaccine had a significantly improved ADG (+34 g/d, p = 0. 047), resulting in a 5-day earlier shipment to slaughter. The group also had a shorter and lower PCV2 load in serum during the fattening period, and an improved lung lesions score. In both groups, three pigs died during the peak PCV2 viraemia (16–23 weeks of age). Immunohistochemistry of the lymph nodes showed that in the group vaccinated with the bivalent vaccine, none of these pigs had PCV2-like lesions, while 2 out of the 3 from the other group did. Results suggest that the added PCV2 valence in the vaccination protocol helps countering the negative impact of subclinical PCV2 infection on growth. The calculated return on investment of the added PCV2 vaccine valence was €1.7 extra revenue per slaughtered pig (€ 39 additional revenue per sow and per year), despite the fact that the cost of the bivalent vaccine was higher than the monovalent M. hyopneumoniae vaccine. CONCLUSION: In this healthy conventional sow farm, the combined M. hyopneumoniae and PCV2 vaccination was efficacious, convenient to administer and profitable. |
format | Online Article Text |
id | pubmed-5772722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57727222018-01-26 Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm Duivon, Didier Corrégé, Isabelle Hémonic, Anne Rigaut, Martial Roudaut, David Jolie, Rika Porcine Health Manag Research BACKGROUND: A controlled randomized trial was performed on a well-managed conventional French 180-sow farm. The trial compared the growth performances of piglets vaccinated at weaning (single shot) either with a commercial monovalent Mycoplasma hyopneumoniae bacterin vaccine or with a commercial bivalent vaccine (Porcilis® PCV M Hyo) against M. hyopneumoniae and porcine circovirus 2 (PCV2). The farm’s porcine reproductive and respiratory syndrome status was stable, and most diseases (enzootic pneumonia, atrophic rhinitis, post-weaning multisystemic wasting syndrome) were controlled by routine vaccination. RESULTS: During the post-weaning phase, the growth performances of the piglets vaccinated with the bivalent vaccine were not significantly different from those vaccinated with the monovalent vaccine. However, during the fattening phase the group vaccinated with the bivalent vaccine had a significantly improved ADG (+34 g/d, p = 0. 047), resulting in a 5-day earlier shipment to slaughter. The group also had a shorter and lower PCV2 load in serum during the fattening period, and an improved lung lesions score. In both groups, three pigs died during the peak PCV2 viraemia (16–23 weeks of age). Immunohistochemistry of the lymph nodes showed that in the group vaccinated with the bivalent vaccine, none of these pigs had PCV2-like lesions, while 2 out of the 3 from the other group did. Results suggest that the added PCV2 valence in the vaccination protocol helps countering the negative impact of subclinical PCV2 infection on growth. The calculated return on investment of the added PCV2 vaccine valence was €1.7 extra revenue per slaughtered pig (€ 39 additional revenue per sow and per year), despite the fact that the cost of the bivalent vaccine was higher than the monovalent M. hyopneumoniae vaccine. CONCLUSION: In this healthy conventional sow farm, the combined M. hyopneumoniae and PCV2 vaccination was efficacious, convenient to administer and profitable. BioMed Central 2018-01-18 /pmc/articles/PMC5772722/ /pubmed/29375890 http://dx.doi.org/10.1186/s40813-017-0077-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Duivon, Didier Corrégé, Isabelle Hémonic, Anne Rigaut, Martial Roudaut, David Jolie, Rika Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm |
title | Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm |
title_full | Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm |
title_fullStr | Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm |
title_full_unstemmed | Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm |
title_short | Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm |
title_sort | field evaluation of piglet vaccination with a mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and m. hyopneumoniae in a conventional french farrow-to-finish farm |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772722/ https://www.ncbi.nlm.nih.gov/pubmed/29375890 http://dx.doi.org/10.1186/s40813-017-0077-y |
work_keys_str_mv | AT duivondidier fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm AT corregeisabelle fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm AT hemonicanne fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm AT rigautmartial fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm AT roudautdavid fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm AT jolierika fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm |